化学
共价键
激酶
生物化学
磷酸化
细胞生物学
酶
蛋白激酶A
作者
Gerjan de Bruin,Tjeerd Barf
出处
期刊:RSC drug discovery series
日期:2018-10-31
卷期号:: 61-96
被引量:1
标识
DOI:10.1039/9781788013093-00061
摘要
In recent years, the field of covalent kinase drug discovery has been rapidly evolving. Several covalent kinase inhibitors (such as afatinib, osimertinib, ibrutinib and acalabrutinib) have obtained market approval or are currently in early and advanced clinical studies. Both covalent irreversible and covalent reversible kinase inhibitors have been discovered, providing an opportunity to target specific kinases, mutations and or pharmacokinetic (PK)/pharmacodynamic (PD) profiles. This chapter will give an overview of the state-of-the-art of covalent kinase drug discovery. First, the concept of covalent enzyme inhibition will be introduced and a comparison to non-covalent inhibitors will be made, highlighting possible advantages and disadvantages of such mechanisms of action (MOA). The importance of selectivity, drug-target residence times and inhibitor kinetics will also be discussed. Finally, a literature overview of irreversible and reversible covalent kinase inhibitors that are currently on the market or in the clinical testing phase will be presented.
科研通智能强力驱动
Strongly Powered by AbleSci AI